Mary Rozenman PhD, BA

Mary Rozenman has more than 15 years of scientific expertise, company building and transaction leadership in the biotechnology industry. She is currently Chief Financial Officer/ Chief Business Officer of insitro company applying machine learning to drug discovery and development. There, she leads strategic and operational functions including finance and accounting, strategy, business development, investor relations, and corporate communications, as well as project and portfolio management.

Prior to Insitro, she was Senior Vice President of Corporate Development and Strategy at Aimmune Therapeutics, where she led business development and partnerships with companies such as Regeneron/Sanofi and Nestlé Health Science and raised more than $650 million in capital through a range of private and public transactions including leadership of the company’s 2015 IPO. Before Aimmune, she was a venture investor at Longitude Capital focused on biotechnology and a junior partner at McKinsey & Co focused on pharmaceuticals and corporate finance. Dr. Rozenman holds a Ph.D. in Organic Chemistry and Chemical Biology from Harvard University and a BA in Biochemistry and Russian literature from Columbia University.